In prospective research with 123 patients receiving platinum chemotherapeutics, Tanase et al.57 reported that urine levels of KIM-1, NGAL, and cystatin C showed a statistically significant elevation on day three after treatment commencement in AKI patients. The gene discussed is LCN2; the disease is acute kidney injury.